We are monitoring the impact of COVID-19 on Europe Zika Virus Vaccines Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 5813
Share on
Share on

Europe Zika Virus Vaccines Market Research Report - Segmented By Type, End-user, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Trends and Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 5813
Pages: 145

Europe Zika Virus Vaccines Market Size (2020 to 2025)

The size of the Zika Virus Vaccines Market in Europe was worth USD 4.19 billion in 2020. It is estimated to be growing at a CAGR of 4.32% to reach USD 5.17 billion by 2025.

Zika virus is a mosquito-borne fever caused by Aedes mosquitoes when they are active in the day-time. It is similar to yellow fever, West Nile virus, and dengue. Zika vaccines are developed to prevent and control diseases caused by the zika virus. This disease has no symptoms or sometimes very mild symptoms like a minimal form of dengue fever, skin rash, and joint pains. It is transmitted sexually from the infected person or the infected pregnant woman to the baby.

Government initiatives, a large population of the patients, an increase in healthcare expenditure, and disposable income drive the vaccine market. Reimbursement, favorable government policies, close attention towards pregnant women, a rise in incidences in the Zika virus, and advanced technology developments in health care are driving the European Zika virus vaccine market. An increase in understanding of Zika virus infection and investments made by the private companies causes the European Zika virus vaccine market.

World Health Organization (WHO) has announced that the Zika virus is less widespread in some areas or communities, etc., which are the factors that are restraining the local market. The requirement of an enormous amount of money investments in the development of vaccines may also control the market's growth. Lack of awareness is also projected to hinder the expansion of the European Zika virus vaccine market.

The opportunities in the European Zika virus vaccines market include the need to prevent the virus, immunization of vaccines, treatment for Zika linked congenital disabilities, i.e., newborn babies diagnosed with the link of the Zika virus and other supporting factors within the area. The factors mentioned in the challenges have resulted in the interest of the pharmaceutical organizations to invest and capitalize on the growth challenges. 

The crucial challenges that come in face to face with the healthcare and government in the regions like Europe are the continuous spreading of the Zika virus and the deficiency of preventive and effective medical solutions towards the treatment. To overcome these challenges, the government and other research institutes are motivating and supporting the pharmaceutical regions to invest, fund, and allot infrastructure and outsourcing of labor. The in-depth analysis provides insight into the growth and challenges involved in the European Zika virus vaccines Market.

This report on European Zika Vaccines Market has been segmented & sub-segmented into the following categories:

  • By Type: Therapeutic Vaccines & Preventive Vaccines
  • By End-User: Hospitals, Clinics, Research Institutes & Others
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic, and Rest of Europe

Regionally, In Europe, Germany leads the zika virus vaccine market, followed by France and U.K. The market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness and favorable reimbursement policies.

The opportunities for the European Zika virus vaccines market include the need to prevent the virus, immunization of vaccines, treatment for Zika linked congenital disabilities, i.e., newborn babies diagnosed with links of the Zika virus and other supporting factors within the area. The factors mentioned in the challenges have resulted in the pharmaceutical organizations' interest in investing and capitalizing on the growth challenges.

The challenges the healthcare institutes and government face in Europe are the constant spread of the Zika virus and the lack of preventive and effective medical solutions. The government and several research institutes support and invest, fund, and allot infrastructure and labor outsourcing in the pharmaceutical regions.

Germany leads the Zika virus vaccine market, followed by France and U.K. The market is expected to grow strongly during the forecast period in Europe due to various factors such as increasing awareness and healthy compensation plans.

Prominent companies in the Europe Zika virus vaccines market profiled in this report are Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Type                              

                                5.1.1 Introduction           

                                5.1.2 Therapeutic Vaccines         

                                5.1.3 Preventive Vaccines           

                                5.1.4 Y-o-Y Growth Analysis, By Type     

                                5.1.5 Market Attractiveness Analysis, By Type   

                                5.1.6 Market Share Analysis, By Type     

                5.2 End-user                      

                                5.2.1 Introduction           

                                5.2.2 Hospitals  

                                5.2.3 Clinics        

                                5.2.4 Research institutes              

                                5.2.5 Others      

                                5.2.6 Y-o-Y Growth Analysis, By End-user             

                                5.2.7 Market Attractiveness Analysis, By End-user           

                                5.2.8 Market Share Analysis, By End-user             

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type

                                                6.1.3.3 By End-user

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type

                                                6.1.4.3 By End-user

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type

                                                6.1.5.3 By End-user

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Takeda Pharmaceutical Co. Ltd.,                        

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 NewLink Genetics Co.,                          

                8.3 Immunovaccine Inc.,                              

                8.4 GeneOne Life Science Inc.,                  

                8.5 GlaxoSmithKline plc.,                             

                8.6 ., Inovio Pharmaceuticals, Inc.,                           

                8.7 Bharat Biotech International Ltd.,                     

                8.8 Hawaii Biotech Inc.,                 

                8.9 Sanofi S.A.                  

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms Clinics, Research with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Europe Zika Virus Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  2. Europe Therapeutic Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  3. Europe Preventive Vaccines Market, By Region, From 2020 to 2025 (USD Billion)
  4. Europe Zika Virus Vaccines Market, By End-user, From 2020 to 2025 (USD Billion)
  5. Europe Hospitals Market, By Region, From 2020 to 2025 (USD Billion)
  6. Europe Clinics Market, By Region, From 2020 to 2025 (USD Billion)
  7. Europe Research institutes Market, By Region, From 2020 to 2025 (USD Billion)
  8. Europe Others Market, By Region, From 2020 to 2025 (USD Billion)
  9. U.K. Zika Virus Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  10. U.K. Zika Virus Vaccines Market, By End-user, From 2020 to 2025 (USD Billion)
  11. Germany Zika Virus Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  12. Germany Zika Virus Vaccines Market, By End-user, From 2020 to 2025 (USD Billion)
  13. France Zika Virus Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  14. France Zika Virus Vaccines Market, By End-user, From 2020 to 2025 (USD Billion)
  15. Italy Zika Virus Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  16. Italy Zika Virus Vaccines Market, By End-user, From 2020 to 2025 (USD Billion)
  17. Spain Zika Virus Vaccines Market, By Type, From 2020 to 2025 (USD Billion)
  18. Spain Zika Virus Vaccines Market, By End-user, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample